Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Geriatric MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Guidelines for improving the care of the older person with diabetes mellitus.J Am Geriatr Soc. 2003; 51: S265-S280
- Standards of medical care in diabetes—2009.Diabetes Care. 2009; 32: S13-S61
- Percentage of civilian, noninstitutionalized population with diagnosed diabetes, by age, United States, 1980–2006.(Available at:) (Accessed May 10, 2009)
Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2007;2008.
- Incidence of diagnosed diabetes per 1,000 population aged 18–79 years, by age, United States, 1980–2007.(Available at) (Accessed May 10, 2009)
- Macrovascular complication of diabetes in older adults.in: Munshi M.N. Lipsitz L.A. Geriatric diabetes. Informa Healthcare USA, Inc, New York2007: 169-182
- Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study.Diabetes Care. 2001; 24: 1233-1239
- 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study.Arch Intern Med. 2006; 166: 71-78
- Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.Lancet. 2002; 359: 2072-2077
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.Lancet. 2006; 368: 1096-1105
- Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med. 2002; 346: 393-403
- Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.Diabetes Res Clin Pract. 2005; 67: 152-162
- Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.Diabetes Care. 1997; 20: 537-544
- The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).Diabetologia. 2006; 49: 289-297
- XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.Diabetes Care. 2004; 27: 155-161
- Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.N Engl J Med. 2001; 344: 1343-1350
- The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes.J Gerontol A Biol Sci Med Sci. 2006; 61: 1075-1081
- Impaired fasting glucose and impaired glucose tolerance: implications for care.Diabetes Care. 2007; 30: 753-759
- Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.Lancet. 1999; 353: 617-622
- Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.N Engl J Med. 2003; 348: 383-393
- Effect of a multifactorial intervention on mortality in type 2 diabetes.N Engl J Med. 2008; 358: 580-591
- Effects of intensive glucose lowering in type 2 diabetes.N Engl J Med. 2008; 358: 2545-2559
- Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.Am J Cardiol. 2007; 99: 4i-20i
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med. 2008; 358: 2560-2572
- Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.J Diabet Complications. 2003; 17: 314-322
- Glucose control and vascular complications in veterans with type 2 diabetes.N Engl J Med. 2009; 360: 129-139
- 10-year follow-up of intensive glucose control in type 2 diabetes.N Engl J Med. 2008; 359: 1577-1589
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet. 2005; 366: 1279-1289
- The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study.J Am Coll Cardiol. 2007; 49: 1772-1780
- Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.Lancet. 2004; 364: 685-696
- Analysis of efficacy and safety in patients aged 65-75 years at randomization: collaborative atorvastatin diabetes study (CARDS).Diabetes Care. 2006; 29: 2378-2384
- What's in the CARDS?.Diabet Med. 2006; 23: 711-714
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.Lancet. 2003; 361: 1149-1158
- Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.J Hypertens. 2001; 19: 1139-1147
- Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA).Diabetes Care. 2005; 28: 1151-1157
- Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.Lancet. 2006; 368: 919-928
- Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med. 2005; 352: 1425-1435
- Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.Diabetes Care. 2006; 29: 1220-1226
- Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?.Am J Cardiol. 2004; 93: 154-158
- Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial.Eur Heart J. 2006; 27: 2323-2329
- Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med. 2004; 350: 1495-1504
- Design of the pravastatin or atorvastatin evaluation and infection therapy (PROVE IT)-TIMI 22 trial.Am J Cardiol. 2002; 89: 860-861
- Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention—a Lescol Intervention Prevention Study (LIPS) substudy.Am Heart J. 2005; 149: 329-335
- Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial.JAMA. 2002; 287: 3215-3222
- Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris.Am J Cardiol. 1995; 76: 474-479
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.N Engl J Med. 1998; 339: 1349-1357
- Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.Diabetes Care. 2003; 26: 2713-2721
- Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.Circulation. 1998; 98: 2513-2519
- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.N Engl J Med. 1996; 335: 1001-1009
- The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators.N Engl J Med. 1997; 336: 153-162
- Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.Diabetes. 1999; 48: 1289-1294
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet. 1994; 344: 1383-1389
- The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.Diabetes Care. 1997; 20: 469-471
- Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).Am J Cardiol. 1995; 76: 64C-68C
- Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.Am J Cardiol. 2000; 86: 257-262
- Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).Diabetes Care. 1997; 20: 614-620
- Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN).Diabetes Care. 2006; 29: 1478-1485
- Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience.Eur Heart J. 1999; 20: 725-741
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.Lancet. 2002; 360: 7-22
- MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Lancet. 2003; 361: 2005-2016
- Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT).Diabetes Care. 2003; 26: 1513-1517
- Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.N Engl J Med. 1999; 341: 410-418
- Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the department of veterans affairs high-density lipoprotein intervention trial (VA-HIT).Arch Intern Med. 2002; 162: 2597-2604
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.Lancet. 2005; 366: 1849-1861
- Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].Cardiovasc Diabetol. 2005; 4: 13
- Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study.Lancet. 2001; 357: 905-910
- The Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project Group.Diabetologia. 1996; 39: 1655-1661
- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.Lancet. 2005; 366: 895-906
- The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.J Hypertens. 2008; 26: 2103-2111
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA. 2002; 288: 2981-2997
- Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Research Group.Am J Hypertens. 1996; 9: 342-360
- Setting the record straight.Ann Intern Med. 2004; 141: 39-46
- Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists' Collaboration meta-analysis.J Hum Hypertens. 2005; 19: 851-853
- Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Arch Intern Med. 2005; 165: 1401-1409
- The Hypertension Optimal Treatment (HOT) Study—patient characteristics: randomization, risk profiles, and early blood pressure results.Blood Press. 1994; 3: 322-327
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet. 1998; 351: 1755-1762
- Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.J Hypertens. 2001; 19: 1149-1159
- The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.N Engl J Med. 1998; 338: 645-652
- Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial.Am J Cardiol. 1998; 82: 9R-14R
- Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial.Am Heart J. 2003; 145: 993-998
- The ABCD (Appropriate Blood Pressure Control in Diabetes) trial. Rationale and design of a trial of hypertension control (moderate or intensive) in type II diabetes.Online J Curr Clin Trials. 1993; 2 (Doc No 104:[6250 words; 6128 paragraphs])
- Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.N Engl J Med. 2000; 343: 1969
- Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial.Nat Clin Pract Nephrol. 2007; 3: 428-438
- Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization.Aging (Milano). 1991; 3: 287-302
- Benefit of antihypertensive treatment in the diabetic patients enrolled in the Systolic Hypertension in Europe (Syst-Eur) trial.Cardiovasc Drugs Ther. 2000; 14: 49-53
- Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.Lancet. 1997; 350: 757-764
- Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly.Arch Intern Med. 1998; 158: 1681-1691
- Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. systolic hypertension in Europe Trial Investigators.N Engl J Med. 1999; 340: 677-684
- Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.JAMA. 1991; 265: 3255-3264
- Long-term follow-up after tight control of blood pressure in type 2 diabetes.N Engl J Med. 2008; 359: 1565-1576
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.Lancet. 2007; 370: 829-840
- The BENEDICT Group. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.Control Clin Trials. 2003; 24: 442-461
- Preventing microalbuminuria in type 2 diabetes.N Engl J Med. 2004; 351: 1941-1951
- Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT).Diabetes Care. 2008; 31: 1629-1634
- Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.Diabetologia. 2005; 48: 1980-1987
- The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).J Renin Angiotensin Aldosterone Syst. 2000; 1: 328-335
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med. 2001; 345: 861-869
- Losartan and end-organ protection—lessons from the RENAAL study.Clin Cardiol. 2005; 28: 136-142
- Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.Diabetes Care. 2006; 29: 2210-2217
- The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.Control Clin Trials. 2000; 21: 383-396
- Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).BMJ. 2004; 328: 495
- The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.Can J Cardiol. 1996; 12: 127-137
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet. 2000; 355: 253-259
- Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.Circulation. 2001; 104: 522-526
- Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.Diabetes Metab Res Rev. 2002; 18: S82-S85
- Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.Am Heart J. 2007; 154: 448-453
- The HOPE Study (Heart Outcomes Prevention Evaluation).J Renin Angiotensin Aldosterone Syst. 2000; 1: 18-20
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med. 2000; 342: 145-153
- Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.Diabetes Care. 2003; 26: 3264-3272
- Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.Lancet. 2001; 357: 89-95
- Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.JAMA. 2008; 300: 2134-2141
- Intensive glycemic control in the ACCORD and ADVANCE trials.N Engl J Med. 2008; 358: 2630-2633
- Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College Of Cardiology Foundation and the American Heart Association.J Am Coll Cardiol. 2009; 53: 298-304
- Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).Am J Cardiol. 1997; 80: 287-293
- Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA. 1998; 279: 1615-1622
- Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).Circulation. 1998; 97: 1440-1445
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.Lancet. 2002; 360: 1623-1630
- Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.BMJ. 1994; 308: 81-106
- Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group.Am J Med. 1998; 105: 494-499
- Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study.Diab Vasc Dis Res. 2006; 3: 202-215
- Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial.Diabetes Care. 2007; 30: 1374-1383
- Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.Control Clin Trials. 2003; 24: 610-628
- Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.JAMA. 2005; 294: 716-724
- Relationship between number of medical conditions and quality of care.N Engl J Med. 2007; 356: 2496-2504
- Descriptive epidemiology of diabetes.in: Munshi M.N. Lipsitz L.A. Geriatric diabetes. Informa Healthcare USA, Inc, New York2007: 1-9
Article info
Identification
Copyright
© 2009 Published by Elsevier Inc.
